罗培干扰素α-2b

{{Infobox drug
| drug_name =
| INN =
| type =
| image =
| width =
| alt =
| caption =

| pronounce =
| tradename = 百斯瑞明（Besremi）
| Drugs.com =
| MedlinePlus =
| licence_CA =
| licence_EU = yes
| DailyMedID = Ropeginterferon_alfa
| licence_US =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category= Contraindicated
| routes_of_administration = 皮下注射
| class = 干扰素
| ATCvet =
| ATC_prefix = L03
| ATC_suffix = AB15
| ATC_supplemental =

| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment = ，此藥由皮下注射給藥。

歷史
2008年，台灣藥華醫藥發明了該藥物，並於隔年與AOP Orphan藥廠合作進行歐洲區的試驗。在經過7.5年的試驗後，51名患者中有61%達到了治療目標，而FDA也核准該藥物孤兒藥地位。

參考文獻
外部連結
*
*
*